Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 20, 2026

Spelman College Announces MS NOW Anchor and Political Strategist Symone Sanders Townsend as 139th Commencement Speaker

View original at globenewswire.com
Spelman College Announces MS NOW Anchor and Political Strategist Symone Sanders Townsend as 139th Commencement Speaker Atlanta, April 20, 2026 (GLOBE NEWSWIRE) -- (ATLANTA, April 20, 2026) – Spelman College is proud to announce that political and media powerhouse and MS NOW anchor Symone Sanders Townsend will deliver t…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • This extraordinary group of women represents the very standard of leadership and impact we hope our graduates will carry into the world.

    60% confidence
  • As a strategist, communicator and entrepreneur, she embodies the 21st century Renaissance woman that the Spelman woman seeks to emulate.

    60% confidence
  • We are truly thrilled to welcome Symone Sanders Townsend to bring words of inspiration to our graduating Class of 2026. The breadth of Symone's pursuits and depths of her influence make her the ideal person to inspire and move our graduates.

    60% confidence
  • We are equally proud to host a distinguished lineup of dynamic Black women throughout our weekend ceremonies, including visionary humanitarian Claire Babineaux-Fontenot and nationally respected faith leader the Rev. Dr. Gina M. Stewart.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com